Advancements in miRNA Report 2022: Companion Diagnostics for Precision Medicine Presents Opportunities - PR Newswire

2 years ago 43

, /PRNewswire/ -- The "Advancements successful miRNA: Technology Assessment" study has been added to ResearchAndMarkets.com's offering.

Accelerated probe astir RNA-based therapeutics and diagnostics, accompanied by exertion advancements successful sequencing the quality genome, has resulted successful a amended knowing of the relation of miRNA successful biologic pathways, enhancing its imaginable successful some therapeutics and diagnostics. The palmy objective validation of miRNA diagnostic tests has created respective opportunities for miRNA diagnostic companies. The relation of miRNAs arsenic circulating biomarkers makes it imaginable to execute diagnostics from assemblage fluids. The imaginable of miRNA biomarkers successful identifying diseases similar thyroid cancer, bosom cancer, and ovarian crab is being explored.

miRNA diagnostics is expected to turn further and go salient successful point-of-care diagnostics. The improvement of miRNA therapeutics has had its challenges with respect to stableness and transportation issues. However, newer approaches successful the improvement of antagomiRs (miRNA inhibiting drugs) and agomiRs (miRNA replacement therapy) person shown promising results. miRNA companies person witnessed a highly competitory ecosystem and person been acquired by respective larger pharma and diagnostics companies upon their introduction into the objective proceedings stage.

This survey focuses connected the developments successful miRNA therapeutics and diagnostics. It identifies the factors driving involvement successful miRNA probe arsenic good arsenic those affecting the commercialization of miRNA therapeutics and diagnostics. The study besides discusses the emerging opportunities for miRNA exertion companies and highlights concern prospects for manufacture participants and stakeholders.

1. Strategic Imperatives

Why Is It Increasingly Difficult to Grow? The Strategic Imperative 8: Factors Creating Pressure connected miRNA Technology Growth
The Strategic Imperative 8
The Impact of the Top 3 Strategic Imperatives connected the Micro Ribonucleic Acid (miRNA) Industry
Growth Opportunities Fuel the Growth Pipeline Engine
Research Methodology

2. Growth Opportunity Analysis

Scope of Analysis
Segmentation
Growth Drivers
Growth Restraints

3. Assessment of miRNA Therapeutics Landscape: Introduction

Emerging Trends successful miRNA Therapeutics and Diagnostics
Increasing Research successful miRNA Therapeutics and Diagnostics
miRNA Drugs Experiencing Rapid Strides successful Clinical Development
Enablers Accelerating miRNA Research and Commercial Development
Introduction to miRNA Therapeutics
miRNA Therapeutics to Address Complex Diseases
Evolving Approaches successful Developing Antagomirs and miRNA Mimics
Structural Modifications to Increase miRNA Stability

4. Assessment of miRNA Therapeutics Landscape: Application

Application of miRNAs successful Diseases
Oncology
Respiratory Diseases
Neurology
Cardiovascular Diseases
Other Diseases
miRNA Therapeutics successful Development by Companies
Increasing miRNA Research Activities successful Academia

5. Assessment of miRNA Therapeutics Landscape: Delivery and Stability

Challenges successful miRNA Therapeutics
Important miRNA Therapeutics Delivery Systems
Comparison of miRNA Delivery Systems
Developing Newer Delivery Systems
Future Prospects of miRNA Therapeutics

6. Assessment of miRNA Diagnostics Landscape: Introduction

Introduction to miRNA Diagnostics
Benefits of miRNA Diagnostics
Opportunities for Using miRNA successful Diagnostics
Emerging Developments successful miRNA Diagnostics

7. Assessment of miRNA Diagnostics Landscape: Application

Oncology
Neurological Diseases
Cardiovascular and Other Diseases

8. Assessment of miRNA Therapeutics & Diagnostics: Funding Landscape

M&A miRNA Therapeutics
M&A miRNA Diagnostics
Funding Landscape of miRNA companies
miRNA - Important Takeaways

9. Growth Opportunity Universe

Growth Opportunity 1: Improved Targeted Delivery Systems to Reduce Off-target Effects and Toxicity
Growth Opportunity 2: Development of POC Diagnostics to Detect Circulating Biomarkers Across Diseases
Growth Opportunity 3: Companion Diagnostics for Precision Medicine

10. Appendix